NasdaqGM:PAHCPharmaceuticals
Phibro Animal Health (PAHC) Margin Rebound And EPS Surge Test Cautious Growth Narratives
Phibro Animal Health Q2 2026 earnings snapshot
Phibro Animal Health (PAHC) just posted Q2 2026 results with revenue of US$373.9 million and basic EPS of US$0.68, while trailing twelve month figures stand at US$1.5 billion in revenue and basic EPS of US$2.27. The company has seen quarterly revenue move from US$309.3 million in Q2 2025 to US$373.9 million in Q2 2026, with basic EPS shifting from US$0.08 to US$0.68 over the same period. This sets up a scenario where investors may weigh these...